Biodexa Pharmaceuticals Plc
BDRX
$7.45
-$0.06-0.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.84% | -14.27% | 28.91% | 29.13% | 6.56% |
| Total Depreciation and Amortization | 8.97% | 2.32% | -12.69% | -12.92% | -4.13% |
| Total Amortization of Deferred Charges | -- | -- | -31.58% | -31.58% | -- |
| Total Other Non-Cash Items | 156.20% | 152.71% | -446.77% | -445.67% | -16.34% |
| Change in Net Operating Assets | 94.78% | 95.10% | -1,062.17% | -1,058.89% | -528.68% |
| Cash from Operations | 27.22% | 31.73% | -160.95% | -160.14% | -24.83% |
| Capital Expenditure | -- | -- | 57.66% | 57.55% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 52.67% | 55.62% | 163.75% | 163.55% | -3,270.67% |
| Cash from Investing | 52.40% | 55.34% | 156.44% | 156.26% | -3,904.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -148.39% | -148.39% | 0.00% | 0.00% | 2.11% |
| Issuance of Common Stock | 31.93% | 31.93% | -24.49% | -24.49% | -25.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 54.72% | 54.72% | -- |
| Cash from Financing | 37.01% | 28.51% | 1.49% | 1.18% | -25.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 373.62% | 356.65% | -569.21% | -567.75% | -138.61% |